Article

Advantage of rare HLA supertype in HIV disease progression.

Children's Hospital Oakland Research Institute, 5700 Martin Luther King Jr. Way Oakland, California 94609, USA.
Nature Medicine (Impact Factor: 28.05). 08/2003; 9(7):928-35. DOI: 10.1038/nm893
Source: PubMed

ABSTRACT The highly polymorphic human leukocyte antigen (HLA) class I molecules help to determine the specificity and repertoire of the immune response. The great diversity of these antigen-binding molecules confers differential advantages in responding to pathogens, but presents a major obstacle to distinguishing HLA allele-specific effects. HLA class I supertypes provide a functional classification for the many different HLA alleles that overlap in their peptide-binding specificities. We analyzed the association of these discrete HLA supertypes with HIV disease progression rates in a population of HIV-infected men. We found that HLA supertypes alone and in combination conferred a strong differential advantage in responding to HIV infection, independent of the contribution of single HLA alleles that associate with progression of the disease. The correlation of the frequency of the HLA supertypes with viral load suggests that HIV adapts to the most frequent alleles in the population, providing a selective advantage for those individuals who express rare alleles.

1 Bookmark
 · 
167 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Genes of the major histocompatibility complex (MHC) encode proteins that recognize foreign antigens and are thus crucial for immune response. In a population of a single host species, parasite-mediated selection drives MHC allelic diversity. However, in a community-wide context, species interactions may modulate selection regimes because the prevalence of a given parasite in a given host may depend on its prevalence in other hosts. By combining network analysis with immunogenetics, we show that host species infected by similar parasites harbour similar alleles with similar frequencies. We further show, using a Bayesian approach, that the probability of mutual occurrence of a functional allele and a parasite in a given host individual is nonrandom and depends on other host-parasite interactions, driving co-evolution within subgroups of parasite species and functional alleles. Therefore, indirect effects among hosts and parasites can shape host MHC diversity, scaling it from the population to the community level.
    Nature Communications 10/2014; 5:5172. DOI:10.1038/ncomms6172 · 10.74 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cellular immunity is pivotal in HIV-1 pathogenesis, but hampered by viral sequence diversity. An approach to minimize this diversity is to focus immunity on conserved proteome sequences; therefore we selected four relatively conserved regions (Gag amino acids 148-214 and 250-335, Env 521-606, and Nef 106-148), each created in three mosaics to provide better coverage of M-group HIV-1 sequences. A conserved region vaccine (CRV) delivering genes for these four regions as equal mixtures of three mosaics (each region at a separate injection site) was compared to a whole protein vaccine (WPV) delivering equimolar amounts of genes for whole Gag, Env, and Nef as clade B consensus sequences (separate injection sites). Three rhesus macaques were vaccinated via three DNA primes and a recombinant adenovirus-5 boost (weeks 0, 4, 8, and 24 respectively). Although CRV inserts were about a fifth that of WPV, the CRV generated comparable magnitude blood CD4(+) and CD8(+) T lymphocyte responses against Gag, Env, and Nef. WPV responses preferentially targeted proteome areas outside the selected conserved regions in direct proportion to sequence lengths, indicating similar immunogenicities for the conserved regions versus the outside regions. The CRV yielded conserved region targeting density that was approximately five-fold that of the WPV. A similar pattern was seen in bronchoalveolar lymphocytes, but quadruple the magnitudes in blood. Overall, these findings demonstrated that the selected conserved regions are highly immunogenic, and that anatomically isolated vaccinations with these regions focuses immunodominance compared to full-length protein vaccination. IMPORTANCE HIV-1 sequence diversity is a major barrier limiting the capability of cellular immunity to contain infection and the ability of vaccines to match circulating viral sequences. To date, vaccines tested in humans have delivered whole proteins or genes for whole proteins, and it is unclear whether including only conserved sequences would yield sufficient cellular immunogenicity. We tested a vaccine delivering genes for four small conserved HIV-1 regions compared to a control vaccine with genes for whole Gag, Env, and Nef. Although the conserved regions ranged from 43 to 86 amino acids and comprised less than one fifth of whole Gag/Env/Nef, the vaccines elicited equivalent total magnitudes of both CD4(+) and CD8(+) T lymphocyte responses. These data demonstrate immunogenicity of these small conserved regions, and the potential for a vaccine to steer immunodominance towards conserved epitopes.
    Journal of Virology 11/2014; 89(2). DOI:10.1128/JVI.02370-14 · 4.65 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Hepatitis C virus (HCV)-specific T cells are key factors in the outcome of acute HCV infection and in protective immunity. This review recapitulates the steps that immunologists have taken in the past 25 years to dissect the role of T cell responses in HCV infection. It describes technical as well as disease-specific challenges that were caused by the inapparent onset of acute HCV infection, the difficulty to identify subjects who spontaneously clear HCV infection, the low frequency of HCV-specific T cells in the blood of chronically infected patients, and the lack of small animal models with intact immune systems to study virus-host interaction. The review provides a historical perspective on techniques and key findings, and identifies areas for future research.
    Antiviral Research 11/2014; 114. DOI:10.1016/j.antiviral.2014.11.009 · 3.43 Impact Factor

Full-text (2 Sources)

Download
261 Downloads
Available from
Jun 4, 2014